Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
Jianming Xu(Chinese PLA General Hospital), Weiguo Su(Tamedia (Switzerland)), Yanhong Deng(Sun Yat-sen University), Chunmei Bai(Shanxi Medical University), Zhiwei Zhou(Sun Yat-sen University), Shukui Qin(81th Hospital of PLA), Dianrong Xiu(Peking University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Songhua Fan, Ying Cheng(Jilin Province Tumor Hospital), Lin Shen(Peking University), Xiaojun Guo(China Banking Regulatory Commission), Yongmei Yin(Nanjing Medical University), Yuxian Bai(Harbin Medical University), Xianjun Yu(Fudan University Shanghai Cancer Center), Tao� Zhang(Ningbo University), Jia Chen(Heilongjiang University of Chinese Medicine), Jie Li(Nanjing University of Chinese Medicine), Zhiping Li(Sichuan University), Tianshu Liu(Sun Yat-sen University), Xianglin Yuan(Tongji Hospital), Xiuwen Wang(Second Hospital of Shandong University), Min Tao(Shanghai East Hospital), Xian Luo(China Banking Regulatory Commission), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xingya Li(Zhengzhou University), Wenhui Lou(Shanghai Medical College of Fudan University), Michael Shi(China Banking Regulatory Commission), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Nong Xu(First Affiliated Hospital Zhejiang University), Hanguang Hu(Zhejiang University)
Cited by 4
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k